Heparin-Induced Thrombocytopenia and Cardiac Surgery

被引：18

作者：

Solanki, Jigna ^{[1
]}

Shenoy, Sundeep ^{[2
]}

Downs, Emily ^{[3
]}

Palkimas, Surabhi ^{[4
]}

Goldman, Svetlana ^{[4
]}

Sharma, Aditya M. ^{[5
]}

机构：

[1] Univ Virginia, Dept Med, Charlottesville, VA 22908 USA

[2] Univ Arizona, Div Cardiovasc Med, Tucson, AZ USA

[3] Univ Virginia, Dept Surg, Charlottesville, VA 22908 USA

[4] Univ Virginia, Dept Pharm, Charlottesville, VA 22908 USA

[5] Univ Virginia, Div Cardiovasc Med, 1215 Lee St, Charlottesville, VA 22908 USA

来源：

SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY | 2019年 / 31卷 / 03期

关键词：

Heparin induced thrombocytopenia; Cardiac surgery; HIT; CORONARY-ARTERY-BYPASS; CARDIOPULMONARY BYPASS; BIVALIRUDIN; ANTIBODIES; ARGATROBAN; DIAGNOSIS; SCORE; COMPLICATIONS; MANAGEMENT; LEPIRUDIN;

D O I：

10.1053/j.semtcvs.2018.10.011

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Heparin-induced thrombocytopenia (HIT) is an immune-mediated condition characterized by thrombocytopenia with possible arterial and/or venous thrombosis. The overall incidence of HIT is low but ranges from 0.1% to 5%.1,2 The incidence can be as high as 3% in patients undergoing cardiac surgery. The use of unfractionated heparin (UFH) is ubiquitous in patients who undergo cardiac procedures and carries a 10-fold higher incidence of HIT over low molecular weight heparin. Patients undergoing cardiac surgery thus form a unique group that warrants specific attention to this clinicopathologic entity considering the relatively high incidence and associated morbidity and mortality with a delay in diagnosis. In this article, we will discuss 5 clinical aspects pertinent to the diagnosis and management of HIT in cardiac surgery patients and review the current literature. © 2018 Elsevier Inc.

引用

页码：335 / 344

页数：10

共 41 条

[1] Heparin induced thrombocytopenia: diagnosis and management update [J].